Curacin A

Curacin A

SCHEMBL61304

C=CC[C@@H](CC/C(C)=C/C=C/CC/C=C\[C@@H]1CSC([C@@H]2C[C@@H]2C)=N1)OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 20/20 1.00
▸ TUBB P07437 20/20 1.00
▸ TUBA3C P0DPH7 20/20 1.00
▸ TUBA1B P68363 20/20 1.00
▸ TUBA4A P68366 20/20 1.00
▸ TUBB4B P68371 20/20 1.00
▸ TUBB3 Q13509 20/20 1.00
▸ TUBB2A Q13885 20/20 1.00
▸ TUBB8 Q3ZCM7 20/20 1.00
▸ TUBA3E Q6PEY2 20/20 1.00
▸ TUBA1A Q71U36 20/20 1.00
▸ TUBA1C Q9BQE3 20/20 1.00
▸ TUBB6 Q9BUF5 20/20 1.00
▸ TUBB2B Q9BVA1 20/20 1.00
▸ TUBB1 Q9H4B7 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Curacin A SCHEMBL14363315 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Curacin A SCHEMBL12379192 1.00 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13135120 0.91 TUBB4A (0.82) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13857390 0.90 TUBB4A (0.82) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29884561 0.88 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12735921 0.62 TUBB4A (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2108688 0.51 — —
SCHEMBL13764202 0.51 TUBB4A (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1775924 0.50 — —
SCHEMBL5058608 0.50 CNR1 (0.41) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7999 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 — — US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 — — US claimed
EP-4479042-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-12-25 — — EP claimed
US-20240400468-A1 Bionutritional Compositions for Plants and Soils ENVIROKURE, INCORPORATED (US) 2024-12-05 — — US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 — — US claimed
EP-4377280-A1 BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS Envirokure Incorporated (US) 2024-06-05 — — EP claimed
WO-2023158514-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-24 — — WO claimed
US-20230263783-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2023-08-24 — — US claimed
WO-2023009636-A1 BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS ENVIROKURE, INCORPORATED (US) 2023-02-02 — — WO claimed
US-11345956-B2 Methods and compositions related to prostate cancer therapeutics THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-31 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 — — US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 — — EP claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 — — WO claimed
US-20020037918-A1 Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin A NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-03-28 — — US claimed
WO-2002006267-A2 SYNTHESIS AND BIOLOGICAL EVALUATION OF ANALOGS OF THE ANTIMITOTIC MARINE NATURAL PRODUCT CURACIN A UNIVERSITY OF PITTSBURGH (US) 2002-01-24 — — WO claimed
WO-2000035865-A2 TUBULIN-BINDING AGENTS TULARIK INC. (US) 2000-06-22 — — WO claimed
WO-1995009630-A1 COMPOUNDS EXHIBITING ANTIPROLIFERATIVE ACTIVITY AGAINST CELLS THE STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 1995-04-13 — — WO claimed
US-5324739-A Curacin A and Curacin B isomers; antimitotics STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 1994-06-28 — — US claimed
Send feedback